BRPI0916121A2 - "métodos para identificar câncer de próstata, método para identificar a presença de uma fusão gênica, kit e uso de uma composição" - Google Patents

"métodos para identificar câncer de próstata, método para identificar a presença de uma fusão gênica, kit e uso de uma composição"

Info

Publication number
BRPI0916121A2
BRPI0916121A2 BRPI0916121A BRPI0916121A BRPI0916121A2 BR PI0916121 A2 BRPI0916121 A2 BR PI0916121A2 BR PI0916121 A BRPI0916121 A BR PI0916121A BR PI0916121 A BRPI0916121 A BR PI0916121A BR PI0916121 A2 BRPI0916121 A2 BR PI0916121A2
Authority
BR
Brazil
Prior art keywords
identifying
kit
composition
methods
prostate cancer
Prior art date
Application number
BRPI0916121A
Other languages
English (en)
Inventor
Arul M Chinnaiyan
Bo Han
Chandan Kumar
Original Assignee
Univ Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan filed Critical Univ Michigan
Publication of BRPI0916121A2 publication Critical patent/BRPI0916121A2/pt
Publication of BRPI0916121A8 publication Critical patent/BRPI0916121A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0916121A 2008-11-18 2009-11-18 métodos para identificar câncer de próstata, composição, kit, método para identificar a presença de uma fusão gênica e uso de uma composição BRPI0916121A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/272,865 US9957569B2 (en) 2005-09-12 2008-11-18 Recurrent gene fusions in prostate cancer
PCT/US2009/064957 WO2010059702A2 (en) 2008-11-18 2009-11-18 Recurrent gene fusions in prostate cancer

Publications (2)

Publication Number Publication Date
BRPI0916121A2 true BRPI0916121A2 (pt) 2015-11-03
BRPI0916121A8 BRPI0916121A8 (pt) 2018-06-19

Family

ID=41668351

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0916121A BRPI0916121A8 (pt) 2008-11-18 2009-11-18 métodos para identificar câncer de próstata, composição, kit, método para identificar a presença de uma fusão gênica e uso de uma composição

Country Status (10)

Country Link
US (1) US9957569B2 (pt)
EP (1) EP2358899A2 (pt)
JP (3) JP2012509068A (pt)
KR (1) KR20110084995A (pt)
CN (1) CN102812130A (pt)
AU (1) AU2009316693B2 (pt)
BR (1) BRPI0916121A8 (pt)
CA (1) CA2744059A1 (pt)
IL (1) IL212964A0 (pt)
WO (1) WO2010059702A2 (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006291054B2 (en) 2005-09-12 2011-10-13 The Brigham And Women's Hospital, Inc. Recurrent gene fusions in prostate cancer
US9957569B2 (en) 2005-09-12 2018-05-01 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
WO2008039774A1 (en) * 2006-09-25 2008-04-03 Mayo Foundation For Medical Education And Research Extracellular and membrane-associated prostate cancer markers
US8338109B2 (en) 2006-11-02 2012-12-25 Mayo Foundation For Medical Education And Research Predicting cancer outcome
ES2376509T3 (es) 2007-07-06 2012-03-14 The Regents Of The University Of Michigan Reordenamientos de genes mipol 1-etv1.
WO2009020521A2 (en) 2007-08-03 2009-02-12 The Brigham And Women's Hospital, Inc. Identification and treatment of estrogen responsive prostate tumors
EP2291553A4 (en) 2008-05-28 2011-12-14 Genomedx Biosciences Inc SYSTEMS AND METHODS FOR THE EXPRESSION-BASED DISTINCTION OF DIFFERENT CLINICAL ILLICIT STADIAS IN PROSTATE CANCER
US10407731B2 (en) 2008-05-30 2019-09-10 Mayo Foundation For Medical Education And Research Biomarker panels for predicting prostate cancer outcomes
JP2012514475A (ja) * 2009-01-09 2012-06-28 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 癌における再現性の遺伝子融合物
EP2435584B1 (en) 2009-05-26 2016-07-13 Quest Diagnostics Investments Incorporated Methods for detecting gene dysregulations
US9938582B2 (en) * 2009-09-17 2018-04-10 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
WO2011079191A1 (en) 2009-12-23 2011-06-30 Quest Diagnostics Investments Incorporated Tmprss2 for the diagnosis of prostate disease
US9315802B2 (en) 2009-12-30 2016-04-19 Quest Diagnostics Investments Incorporated RNA isolation from soluble urine fractions
US8945556B2 (en) 2010-11-19 2015-02-03 The Regents Of The University Of Michigan RAF gene fusions
CN106434870A (zh) 2010-11-19 2017-02-22 密执安大学评议会 ncRNA及其用途
US20130267443A1 (en) 2010-11-19 2013-10-10 The Regents Of The University Of Michigan ncRNA AND USES THEREOF
US9663781B2 (en) 2010-12-30 2017-05-30 Quest Diagnostics Investments Incorporated Diagnosis of prostate cancer
CA2858581A1 (en) 2011-12-13 2013-06-20 Genomedx Biosciences, Inc. Cancer diagnostics using non-coding transcripts
CN114134029A (zh) 2012-02-13 2022-03-04 纽莫德克斯莫勒库拉尔公司 用于处理和检测核酸的微流体盒
US11931740B2 (en) 2012-02-13 2024-03-19 Neumodx Molecular, Inc. System and method for processing and detecting nucleic acids
CA2881627A1 (en) 2012-08-16 2014-02-20 Genomedx Biosciences Inc. Cancer diagnostics using biomarkers
US20140120544A1 (en) * 2012-10-25 2014-05-01 Neumodx Molecular, Inc. Method and materials for isolation of nucleic acid materials
CN103336914B (zh) * 2013-05-31 2016-05-25 中国人民解放军国防科学技术大学 一种提取荟萃生物标志物的方法及装置
US9994912B2 (en) 2014-07-03 2018-06-12 Abbott Molecular Inc. Materials and methods for assessing progression of prostate cancer
US10870115B2 (en) 2015-08-13 2020-12-22 Dyax Corp. Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activation
EP3504348B1 (en) 2016-08-24 2022-12-14 Decipher Biosciences, Inc. Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
US11208697B2 (en) 2017-01-20 2021-12-28 Decipher Biosciences, Inc. Molecular subtyping, prognosis, and treatment of bladder cancer
CN106866824B (zh) * 2017-03-06 2020-10-27 哈尔滨医科大学 一种抗ddx5的全人源单克隆抗体及其制备方法和应用
WO2018165600A1 (en) 2017-03-09 2018-09-13 Genomedx Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
EP3600371A4 (en) 2017-03-21 2021-06-09 The Regents of The University of Michigan AGAINST ERG THERAPY
AU2018266733A1 (en) 2017-05-12 2020-01-16 Veracyte, Inc. Genetic signatures to predict prostate cancer metastasis and identify tumor aggressiveness
US10964410B2 (en) * 2017-05-25 2021-03-30 Koninklijke Philips N.V. System and method for detecting gene fusion
US10769307B2 (en) 2018-05-30 2020-09-08 Bank Of America Corporation Processing system using natural language processing for performing dataset filtering and sanitization
CN113528660A (zh) * 2020-09-18 2021-10-22 深圳汇芯生物医疗科技有限公司 前列腺癌的风险评估装置
CN112522404B (zh) * 2020-12-10 2023-06-09 珠海中科先进技术研究院有限公司 一种用于检测前列腺癌的多重荧光pcr试剂盒

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4109496A (en) * 1977-12-20 1978-08-29 Norris Industries Trapped key mechanism
US4323546A (en) * 1978-05-22 1982-04-06 Nuc Med Inc. Method and composition for cancer detection in humans
GB2043675B (en) * 1979-03-08 1983-02-23 British Gas Corp Gas oil purification
US4873191A (en) * 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4965188A (en) * 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
DE3785591T2 (de) * 1986-01-10 1993-09-02 Amoco Corp Kompetitiver homogener test.
US4800159A (en) * 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5080891A (en) * 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5283174A (en) * 1987-09-21 1994-02-01 Gen-Probe, Incorporated Homogenous protection assay
US5130238A (en) * 1988-06-24 1992-07-14 Cangene Corporation Enhanced nucleic acid amplification process
US4968103A (en) * 1988-07-22 1990-11-06 Photofinish Cosmetics Inc. Method of making a brush
US5225326A (en) * 1988-08-31 1993-07-06 Research Development Foundation One step in situ hybridization assay
KR100242252B1 (ko) * 1989-07-11 2000-03-02 다니엘 엘. 캐시앙 핵산서열의 증폭방법
CA2020958C (en) * 1989-07-11 2005-01-11 Daniel L. Kacian Nucleic acid sequence amplification methods
US5614396A (en) * 1990-06-14 1997-03-25 Baylor College Of Medicine Methods for the genetic modification of endogenous genes in animal cells by homologous recombination
US5455166A (en) * 1991-01-31 1995-10-03 Becton, Dickinson And Company Strand displacement amplification
US5270184A (en) * 1991-11-19 1993-12-14 Becton, Dickinson And Company Nucleic acid target generation
US5545524A (en) * 1991-12-04 1996-08-13 The Regents Of The University Of Michigan Compositions and methods for chromosome region-specific probes
EP0552108B1 (en) * 1992-01-17 1999-11-10 Lakowicz, Joseph R. Energy transfer phase-modulation fluoro-immunoassay
EP0672131B1 (en) 1992-10-30 2003-12-17 The General Hospital Corporation A novel cell cycle control protein
US5925517A (en) * 1993-11-12 1999-07-20 The Public Health Research Institute Of The City Of New York, Inc. Detectably labeled dual conformation oligonucleotide probes, assays and kits
JP3448090B2 (ja) * 1994-02-16 2003-09-16 浜松ホトニクス株式会社 エネルギー移動検出法およびその装置
US20050214309A1 (en) * 1994-03-18 2005-09-29 Hinrichs Steven H Methods and compositions for modulating transcription factor activity
US5648211A (en) 1994-04-18 1997-07-15 Becton, Dickinson And Company Strand displacement amplification using thermophilic enzymes
JP3189000B2 (ja) * 1994-12-01 2001-07-16 東ソー株式会社 特定核酸配列の検出方法
US5856125A (en) 1995-06-05 1999-01-05 The United States Of America As Represented By The Department Of Health And Human Services ETS2 repressor factor (ERF) genetic locus and its products
US5710029A (en) * 1995-06-07 1998-01-20 Gen-Probe Incorporated Methods for determining pre-amplification levels of a nucleic acid target sequence from post-amplification levels of product
US5854206A (en) * 1995-08-25 1998-12-29 Corixa Corporation Compounds and methods for treatment and diagnosis of prostate cancer
US6121489A (en) * 1996-03-05 2000-09-19 Trega Biosciences, Inc. Selectively N-alkylated peptidomimetic combinatorial libraries and compounds therein
KR19990087802A (ko) * 1996-03-15 1999-12-27 길리스 스티브 전립선암의 면역치료 및 면역진단을 위한 화합물 및 방법
DE69738687D1 (de) * 1996-04-12 2008-06-26 Phri Properties Inc Sonden, kits und assays
AU4566997A (en) 1996-10-07 1998-05-05 Meat And Livestock Commission Assay for duroc muscle fibre type
US7125969B1 (en) 1996-11-27 2006-10-24 The Regents Of The University Of California ETS-related gene overexpressed in human breast and epithelial cancers
US20030185830A1 (en) * 1997-02-25 2003-10-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
PL196260B1 (pl) * 1997-02-25 2007-12-31 Corixa Corp Polipeptyd, cząsteczka DNA, komórka gospodarza, białko fuzyjne, kompozycje farmaceutyczne i szczepionki do leczenia raka prostaty
US6395278B1 (en) 1997-02-25 2002-05-28 Corixa Corporation Prostate specific fusion protein compositions
US6943236B2 (en) 1997-02-25 2005-09-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6043033A (en) 1997-02-27 2000-03-28 Incyte Pharmaceuticals, Inc. Human prostate-associated protease
US20020119531A1 (en) 1997-02-27 2002-08-29 Olga Bandman Prostate-associated protease antibody
US20030103981A1 (en) 1997-02-27 2003-06-05 Incyte Genomics, Inc. Methods of use of a prostate-associated protease in the diagnosis and treatment of prostate cancer
AU6449398A (en) * 1997-03-07 1998-09-22 Clare Chemical Research Llc Fluorometric detection using visible light
US6080912A (en) * 1997-03-20 2000-06-27 Wisconsin Alumni Research Foundation Methods for creating transgenic animals
ES2402947T3 (es) 1997-04-10 2013-05-10 Stichting Katholieke Universiteit University Medical Centre Nijmegen PCA3, genes PCA3 y métodos de uso
US6187799B1 (en) * 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
US7037667B1 (en) 1998-06-01 2006-05-02 Agensys, Inc. Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
DE69943020D1 (de) 1998-06-01 2011-01-20 Agensys Inc Tumorantigen verwendbar in der diagnose und therapie von prostata und dickdarm-krebs
CA2331266A1 (en) 1998-06-16 1999-12-23 The Regents Of The University Of California Exons 4 and 7 encode separate transactivating and chromatin localizing domains in esx
WO2000000605A1 (en) 1998-06-29 2000-01-06 Myriad Genetics, Inc. Tmprss2 is a tumor suppressor
ATE440963T1 (de) * 1998-07-02 2009-09-15 Gen Probe Inc Molekulare fackeln
EP1870466A3 (en) 1998-07-14 2008-03-19 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
CA2341142A1 (en) 1998-09-02 2000-03-09 Diadexus Llc A novel method of diagnosing, monitoring, staging, imaging and treating various cancers
US6872811B1 (en) 1998-09-30 2005-03-29 Millennium Pharmaceuticals, Inc. HRPCa9 and HRPCa10 nucleic acids and polypeptides
JP2002531061A (ja) 1998-09-30 2002-09-24 ミレニアム ファーマシューティカルズ インク． 前立腺癌の診断および治療において有用な特異的核酸およびポリペプチドの発現解析
US6573043B1 (en) * 1998-10-07 2003-06-03 Genentech, Inc. Tissue analysis and kits therefor
US6902892B1 (en) 1998-10-19 2005-06-07 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
JP2002527758A (ja) 1998-10-19 2002-08-27 ダイアデクスアス・インコーポレーテッド 前立腺癌を診断、監視、病期分類、イメージング及び治療する方法
US6828429B1 (en) * 1999-03-26 2004-12-07 Henry M. Jackson Foundation For The Advancement Of Military Medicine Prostate-specific gene, PCGEM1, and the methods of using PCGEM1 to detect, treat, and prevent prostate cancer
US6303305B1 (en) * 1999-03-30 2001-10-16 Roche Diagnostics, Gmbh Method for quantification of an analyte
AU4484400A (en) 1999-04-23 2000-11-10 University Of Washington Prostate-specific polynucleotides, polypeptides and their methods of use
WO2000070092A1 (en) 1999-05-14 2000-11-23 Chiron Corporation Expression of ets-domain proteins in cancer
EP1055734B1 (en) * 1999-05-24 2004-10-13 Tosoh Corporation Method for assaying ribonucleic acid
AU2001236519A1 (en) 2000-01-24 2001-07-31 Millennium Pharmaceuitcals, Inc. Identification, assessment, prevention, and therapy of prostate cancer
DE10004102A1 (de) 2000-01-31 2002-06-20 Metagen Pharmaceuticals Gmbh Nachweis von differenzieller Genexpression
AU2001241541A1 (en) 2000-02-17 2001-08-27 Millennium Predictive Medicine, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer
AU2001261676A1 (en) 2000-05-16 2001-11-26 Glaxo Group Limited Method and reagent for the inhibition of erg
WO2002010443A1 (en) 2000-07-27 2002-02-07 The Australian National University Combinatorial probes and uses therefor
WO2002024680A1 (en) * 2000-09-21 2002-03-28 Smithkline Beecham P.L.C. Imidazole derivatives as raf kinase inhibitors
US7892730B2 (en) 2000-12-22 2011-02-22 Sagres Discovery, Inc. Compositions and methods for cancer
US6897024B2 (en) * 2001-05-31 2005-05-24 Stichting Katholieke Universiteit More Particularly The University Medical Centre Nijmegen Nucleic acid molecules comprising the promoter for PCA3, and uses thereof
US20040009481A1 (en) 2001-06-11 2004-01-15 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer
US20030108963A1 (en) 2001-07-25 2003-06-12 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kit, and methods for identification, assessment, prevention and therapy of prostate cancer
US6537811B1 (en) 2001-08-01 2003-03-25 Isis Pharmaceuticals, Inc. Antisense inhibition of SAP-1 expression
US7229774B2 (en) * 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
US7507528B2 (en) 2001-09-06 2009-03-24 Adnagen Ag Method and diagnosis kit for selecting and or qualitative and/or quantitative detection of cells
US6949342B2 (en) 2001-12-21 2005-09-27 Whitehead Institute For Biomedical Research Prostate cancer diagnosis and outcome prediction by expression analysis
AU2003289716A1 (en) 2002-09-12 2004-04-30 Incyte Corporation Molecules for diagnostics and therapeutics
US7790867B2 (en) * 2002-12-05 2010-09-07 Rosetta Genomics Inc. Vaccinia virus-related nucleic acids and microRNA
AU2004209578A1 (en) 2003-02-07 2004-08-19 Diagnocure Inc. Method to detect prostate cancer in a sample
EP2196474A3 (en) 2003-02-14 2010-12-15 Sagres Discovery, Inc. Therapeutic targets in cancer
US20070275915A1 (en) 2003-04-15 2007-11-29 Cell Genesys, Inc. Tmprss2 Regulatory Sequences and Uses Thereof
CA2524572C (en) * 2003-05-01 2018-07-10 Gen-Probe Incorporated Oligonucleotides comprising a molecular switch having enhanced sensitivity to the presence of a mismatch
WO2004097358A2 (en) 2003-05-02 2004-11-11 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human transmembrane serine protease 2 (tmprss2)
AU2004256425A1 (en) * 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
EP1636379A2 (en) 2003-06-26 2006-03-22 Exonhit Therapeutics S.A. Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
CA2432365A1 (en) 2003-06-30 2004-12-30 Jack A. Schalken Specific method of prostate cancer detection based on pca3, and kits therefore
WO2005007090A2 (en) 2003-07-03 2005-01-27 President And Fellows Of Harvard College Inhibitors of the map kinase pathway
WO2005007830A2 (en) 2003-07-14 2005-01-27 Mayo Foundation For Medical Education And Research Methods and compositions for diagnosis, staging and prognosis of prostate cancer
US20050112711A1 (en) * 2003-09-05 2005-05-26 Thomas Jefferson University Diagnosis and monitoring of hepatocellular carcinoma
EP2383350B1 (en) * 2004-05-07 2018-07-11 Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods of diagnosing or treating prostate cancer using the erg gene, alone or in combination with other over or under expressed genes in prostate cancer
CA2576624A1 (en) 2004-08-13 2006-03-16 Millennium Pharmaceuticals, Inc. Genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
CA2898814C (en) * 2004-08-27 2015-12-29 Gen-Probe Incorporated Single-primer nucleic acid amplification methods
US20060275794A1 (en) * 2005-03-07 2006-12-07 Invitrogen Corporation Collections of matched biological reagents and methods for identifying matched reagents
US7638278B2 (en) * 2005-05-13 2009-12-29 The Board Of Trustees Of The Leland Stanford Junior University Markers of DNA copy number alteration for improved prognostication in prostate cancer
AU2006291054B2 (en) * 2005-09-12 2011-10-13 The Brigham And Women's Hospital, Inc. Recurrent gene fusions in prostate cancer
US9957569B2 (en) 2005-09-12 2018-05-01 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
US8541169B2 (en) * 2006-10-10 2013-09-24 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Prostate cancer-specific alternations in ERG gene expression and detection and treatment methods based on those alterations
CA2692441C (en) 2007-07-06 2020-01-21 The Regents Of The University Of Michigan Solute carrier family 45 member 3 (slc45a3) and ets family gene fusions in prostate cancer
US20100305188A1 (en) * 2007-10-03 2010-12-02 Kyowa Hakko Kirin Co., Ltd. Nucleic acid capable of regulating the proliferation of cell
CN102439174B (zh) 2009-02-19 2015-02-04 康奈尔大学 基于检测slc45a3-elk4融合转录子的用于诊断前列腺癌的组合物和方法
US9938582B2 (en) 2009-09-17 2018-04-10 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer

Also Published As

Publication number Publication date
KR20110084995A (ko) 2011-07-26
CN102812130A (zh) 2012-12-05
JP2018019720A (ja) 2018-02-08
AU2009316693A1 (en) 2010-05-27
IL212964A0 (en) 2011-07-31
JP2012509068A (ja) 2012-04-19
WO2010059702A3 (en) 2010-07-29
JP2015177809A (ja) 2015-10-08
AU2009316693B2 (en) 2012-08-23
WO2010059702A2 (en) 2010-05-27
EP2358899A2 (en) 2011-08-24
CA2744059A1 (en) 2010-05-27
US20090239221A1 (en) 2009-09-24
BRPI0916121A8 (pt) 2018-06-19
US9957569B2 (en) 2018-05-01

Similar Documents

Publication Publication Date Title
BRPI0916121A2 (pt) "métodos para identificar câncer de próstata, método para identificar a presença de uma fusão gênica, kit e uso de uma composição"
BRPI0819338A2 (pt) Preparações, métodos e kits úteis para o tratamento de tosse
HRP20170347T1 (hr) Pripravci i postupci za uporabu za protutijela protiv sklerostina
HK1216189A1 (zh) 脂肪肝疾病的生物標誌物及其用法
EP2061899A4 (en) BIOMARKERS FOR PROSTATE CANCER AND METHOD FOR THEIR USE
EP2000543A4 (en) METHOD FOR THE MOLECULAR DIAGNOSIS OF PROSTATIC CANCER AND NECESSARY FOR CARRYING OUT SAID METHOD
HK1142636A1 (en) Biomarkers for pre-diabetes and methods using the same
BRPI0811635A2 (pt) Compostos de arilazol-2-il cianoetilamino, métodos para fazê-los e métodos para o uso dos mesmos
BRPI0807132A2 (pt) enzimas para o tratamento de lignocelulósicos, ácidos nucléicos que codificam as mesmas, e metodos e uso das mesmas
BRPI0908854A2 (pt) composições e métodos para o tratamento de tumor de origem hematopoética
BRPI0716872A2 (pt) Fosfolipases, ácidos nucléicos codificando-as e métodos para fabricação e uso delas
GB0820190D0 (en) Tissue excision tool, kits and methods of using the same
BRPI0822104A2 (pt) Composições antimicrobianas e métodos para o uso das mesmas
ZA200905886B (en) Methods and kits for administering probiotics
BRPI0815138A2 (pt) Métodos e organismos para a produção acoplada a crescimento de 1,4-butanodiol
BR112012000735A2 (pt) "métodos, kits e conjuntos de compostos"
CL2008001682A1 (es) Metodos para el mejoramiento de plantas mediante el uso de informacion directa de secuencias de acidos nucleicos.
BRPI0814330A2 (pt) métodos e kits cirúrgicos
BRPI0807220B1 (pt) composição, e, métodos para aumentar a força de compressão de uma composição e para aumentar a retenção de fragrância de uma composição
GB0603295D0 (en) Methods and kits
BRPI0909885A2 (pt) composição decorativa e método para sua utilização
PL2223121T3 (pl) Sposób różnicowania NZJ i ZJD oraz dalsze rozróżnienie odmian NZJ
EP2011843A4 (en) COMPOSITION FOR AQUEOUS COATING MATERIAL, MANUFACTURING METHOD AND TWO-COMPONENT HARDENABLE AQUEOUS COATING MATERIAL
EP1994411A4 (en) SHORTENED PROTEINS AS CANCER MARKERS
EP2210942A4 (en) GENE ASSOCIATED WITH LIVER CANCER, AND METHOD OF DETERMINING THE RISK OF BEING WITH LIVER CANCER

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements